These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Immune escape and immunotherapy of acute myeloid leukemia. Vago L; Gojo I J Clin Invest; 2020 Apr; 130(4):1552-1564. PubMed ID: 32235097 [TBL] [Abstract][Full Text] [Related]
23. Targeting acute myeloid leukemia through multimodal immunotherapeutic approaches. Przespolewski AC; Portwood S; Wang ES Leuk Lymphoma; 2022 Apr; 63(4):918-927. PubMed ID: 34818963 [TBL] [Abstract][Full Text] [Related]
24. Developmental approaches in immunological control of acute myelogenous leukaemia. Torelli GF; Orsini E; Guarini A; Kell J; Foà R Best Pract Res Clin Haematol; 2001 Mar; 14(1):189-209. PubMed ID: 11355931 [TBL] [Abstract][Full Text] [Related]
25. Hematopoietic stem cell transplantation and immunotherapy for pediatric acute myeloid leukemia: an open challenge. Lucchini G; Bader P Expert Rev Hematol; 2014 Apr; 7(2):291-300. PubMed ID: 24617334 [TBL] [Abstract][Full Text] [Related]
26. An overview of the potential strategies for NK cell-based immunotherapy for acute myeloid leukemia. Sinha C; Cunningham LC Pediatr Blood Cancer; 2016 Dec; 63(12):2078-2085. PubMed ID: 27535002 [TBL] [Abstract][Full Text] [Related]
27. CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia. Bonifant CL; Szoor A; Torres D; Joseph N; Velasquez MP; Iwahori K; Gaikwad A; Nguyen P; Arber C; Song XT; Redell M; Gottschalk S Mol Ther; 2016 Sep; 24(9):1615-26. PubMed ID: 27401038 [TBL] [Abstract][Full Text] [Related]
28. Immunotherapy of acute myeloid leukaemia: development of a whole cell vaccine. Cheuk AT; Guinn BA Front Biosci; 2008 Jan; 13():2022-9. PubMed ID: 17981688 [TBL] [Abstract][Full Text] [Related]
29. New approaches for the immunotherapy of acute myeloid leukemia. Geiger TL; Rubnitz JE Discov Med; 2015 Apr; 19(105):275-84. PubMed ID: 25977190 [TBL] [Abstract][Full Text] [Related]
30. Adoptive transfer of T cells transduced with a chimeric antigen receptor to treat relapsed or refractory acute leukemia: efficacy and feasibility of immunotherapy approaches. Ding G; Chen H Sci China Life Sci; 2016 Jul; 59(7):673-7. PubMed ID: 27142351 [TBL] [Abstract][Full Text] [Related]
31. Acute myeloid leukaemia and the immune system: implications for immunotherapy. Barrett AJ Br J Haematol; 2020 Jan; 188(1):147-158. PubMed ID: 31782805 [TBL] [Abstract][Full Text] [Related]
32. A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia. Zahler S; Bhatia M; Ricci A; Roy S; Morris E; Harrison L; van de Ven C; Fabricatore S; Wolownik K; Cooney-Qualter E; Baxter-Lowe LA; Luisi P; Militano O; Kletzel M; Cairo MS Biol Blood Marrow Transplant; 2016 Apr; 22(4):698-704. PubMed ID: 26785332 [TBL] [Abstract][Full Text] [Related]
33. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Walter RB; Appelbaum FR; Estey EH; Bernstein ID Blood; 2012 Jun; 119(26):6198-208. PubMed ID: 22286199 [TBL] [Abstract][Full Text] [Related]
34. Emerging strategies for high-risk and relapsed/refractory acute myeloid leukemia: novel agents and approaches currently in clinical trials. Sasine JP; Schiller GJ Blood Rev; 2015 Jan; 29(1):1-9. PubMed ID: 25441922 [TBL] [Abstract][Full Text] [Related]
35. [Reaserch Advances in Immunotherapy for Acute Myeloid Leukemia--Review]. Chen ZH; Li YY; Tian C Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Dec; 28(6):2089-2092. PubMed ID: 33283747 [TBL] [Abstract][Full Text] [Related]
36. Immunosuppression and Immunotargeted Therapy in Acute Myeloid Leukemia - The Potential Use of Checkpoint Inhibitors in Combination with Other Treatments. Leufven E; Bruserud Ø Curr Med Chem; 2019; 26(28):5244-5261. PubMed ID: 30907305 [TBL] [Abstract][Full Text] [Related]